Ripretinib
- Generic Name
- Ripretinib
- Brand Names
- Qinlock
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21BrFN5O2
- CAS Number
- 1442472-39-0
- Unique Ingredient Identifier
- 9XW757O13D
- Background
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.
It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors.
- Indication
Ripretinib is indicated to treat adults diagnosed with advanced gastrointestinal stromal tumor (GIST) who have had prior therapy with at least 3 kinase inhibitors, including with imatinib.
- Associated Conditions
- Advanced Gastrointestinal Stromal Tumor (GIST)
A Study of Ripretinib vs Sunitinib in Advanced GIST Patients After Treatment With Imatinib
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2018-09-17
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 453
- Registration Number
- NCT03673501
- Locations
- 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Solove Research Institute, Columbus, Ohio, United States
🇺🇸UCLA Hematology Oncology Center - Main Site, Los Angeles, California, United States
Phase 3 Study of DCC-2618 vs Placebo in Advanced GIST Patients Who Have Been Treated With Prior Anticancer Therapies
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- Drug: Placebo Oral Tablet
- First Posted Date
- 2017-11-27
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 129
- Registration Number
- NCT03353753
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸University of Southern California - Norris, Los Angeles, California, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
- Conditions
- Advanced Systemic MastocytosisGastrointestinal Stromal TumorsAdvanced Cancers
- Interventions
- First Posted Date
- 2015-10-08
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 282
- Registration Number
- NCT02571036
- Locations
- 🇺🇸
Honor Health (GIST, mastocytosis, other solid tumors), Scottsdale, Arizona, United States
🇺🇸UCLA (glial malignancies only), Los Angeles, California, United States
🇺🇸Stanford University Hematology Clinic (mastocytosis), Palo Alto, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.